Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.
That's why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.
Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.
That's why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.
There are more than 1,000 biotech companies in North America alone. They cover a wide range of sectors including pharmaceuticals, biologics, generics, and medical devices.
But finding the right stocks in such a broad industry is no easy task.
That's why we've targeted the best biotech ETF to buy now. It offers investors an excellent way to play the entire industry, without having to pick a specific sector.
It's a common thought that investing in biotech stocks is just too risky for the average investor - but that's not the case.
It's true that biotechnology stocks can be very volatile - especially when companies have developmental drugs going through clinical trials - so they aren't the right stocks for every investor. But when investors are able to limit risk, they can find their portfolio's biggest profits from biotech.
Money Morning's BioScience Investment Strategist Ernie Tremblay recommends investors use this one simple strategy when investing in biotech.
It helps limit risk and maximize profits. Take a look…
Investing in biotech stocks is risky for those who haven't done enough research. But with just a couple of tips, investors can drastically reduce the risk - and go on to benefit from massive windfalls generated by a company's breakthrough drug development.
To find out the best way to minimize risk in biotech investing, we turned to Money Morning's BioScience Investment Specialist Ernie Tremblay.
According to Tremblay, there are a couple of types of biotech stocks that are especially risky…
